CMA: Opium Derivatives Undertakings Released 2026

• The Competition and Markets Authority (CMA) released its opium derivatives undertakings on November 4, 2026.
• These undertakings, which mandated price transparency, are no longer in force and have been removed from the register of remedies.
• They were originally imposed under the monopoly provisions of the Fair Trading Act 1973.
• Specifically, the undertakings required MacFarlan Smith (now Veranova) to publish a maximum price list for opium derivatives.
• Full inquiry documents are available on The National Archives website for public review.

This significant decision means the previously enforced regulatory measures are no longer active, marking a notable change in the oversight of this specific market segment.

The Competition and Markets Authority (CMA) has officially concluded its review of the undertakings related to opium derivatives, announcing their release on November 4, 2026. This significant decision means the previously enforced regulatory measures are no longer active, marking a notable change in the oversight of this specific market segment. The undertakings, which were initially designed to ensure price transparency, have now been formally removed from the CMA's register of remedies that are currently in force.

This action by the CMA signals the end of a long-standing regulatory obligation that impacted key players in the pharmaceutical and chemical sectors. The release of these CMA Opium derivatives undertakings released 2026 effectively lifts the requirement for certain market participants to adhere to specific pricing disclosures, potentially altering competitive dynamics within the industry. The final decision by the Authority was published on the specified date, confirming the cessation of these particular market controls.

These now-released undertakings were originally established under the monopoly provisions of the Fair Trading Act 1973, reflecting a historical regulatory concern regarding market dominance. Their primary objective was to foster greater openness in pricing for opium derivatives, a critical component in various medical and chemical applications. The legal framework of the 1973 Act provided the basis for the CMA, and its predecessors, to impose such remedies to address potential anti-competitive practices.

Specifically, the MacFarlan Smith undertakings mandated that the company publish a comprehensive maximum price list for its opium derivatives. This requirement was a direct consequence of the regulatory assessment under the Fair Trading Act 1973 monopoly provisions, aiming to ensure that customers had clear visibility into the upper limits of pricing for these essential substances. The removal of these undertakings therefore eliminates this specific disclosure requirement for MacFarlan Smith, which rebranded as Veranova in June 2022.

The cessation of these undertakings means that the obligation for Opium derivatives price transparency, as previously enforced, is no longer in effect. This change could have various implications for companies operating in this specialized market, as the regulatory landscape shifts away from mandatory public price disclosures. The removal from the CMA undertakings register remedies signifies a formal end to the Authority's direct intervention in this aspect of market behavior.

For those interested in the full historical context and the detailed rationale behind the original imposition and subsequent release of these undertakings, comprehensive documentation from the inquiry is publicly accessible. A notice detailing the release of the undertakings is available as a PDF document, spanning four pages and approximately 121 KB. Additionally, a separate one-page PDF, about 1.68 MB in size, specifically outlines the opium derivatives undertakings themselves. All related inquiry documents can be found on The National Archives website, providing a complete record for legal and industry professionals.

Lawyers advising clients in the pharmaceutical or chemical sectors, particularly those dealing with opium derivatives, should note that the Competition and Markets Authority (CMA) undertakings requiring price transparency, previously imposed under the Fair Trading Act 1973, are no longer in force as of November 2026. This means the specific regulatory obligation for MacFarlan Smith (and potentially other market participants) to publish maximum price lists for opium derivatives has been lifted, potentially impacting compliance requirements and market strategies.

Source: Original reporting via GOV.UK guidance